CassandraBio
Pipeline dossier

NIH & clinical-trial pipeline signals for AMGEN INC (AMGN)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for AMGN, mapped to public ticker AMGN (CIK 0000318154). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →
Trial → FilingAMGN35% conf

AMGEN INC (AMGN) — PHASE1 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE1) — Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)
trial ↗filings ↗
Trial → FilingAMGN35% conf

AMGEN INC (AMGN) — PHASE3 protocol updated 5 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)
trial ↗filings ↗
Trial → FilingAMGN35% conf

AMGEN INC (AMGN) — PHASE3 protocol updated 5 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)
trial ↗filings ↗

Recent SEC 8-K filings

JSON API for this entity →